Literature DB >> 27038327

Insights Into the Allosteric Inhibition of the SUMO E2 Enzyme Ubc9.

William M Hewitt1, George T Lountos2,3, Katherine Zlotkowski1, Samuel D Dahlhauser1, Lindsey B Saunders1, Danielle Needle2, Joseph E Tropea2, Chendi Zhan4, Guanghong Wei4, Buyong Ma5, Ruth Nussinov5,6, David S Waugh2, John S Schneekloth7.   

Abstract

Conjugation of the small ubiquitin-like modifier (SUMO) to protein substrates is an important disease-associated posttranslational modification, although few inhibitors of this process are known. Herein, we report the discovery of an allosteric small-molecule binding site on Ubc9, the sole SUMO E2 enzyme. An X-ray crystallographic screen was used to identify two distinct small-molecule fragments that bind to Ubc9 at a site distal to its catalytic cysteine. These fragments and related compounds inhibit SUMO conjugation in biochemical assays with potencies of 1.9-5.8 mm. Mechanistic and biophysical analyses, coupled with molecular dynamics simulations, point toward ligand-induced rigidification of Ubc9 as a mechanism of inhibition.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  SUMOylation; Ubc9; X-ray crystallography; allostery; inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27038327      PMCID: PMC4973392          DOI: 10.1002/anie.201511351

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  32 in total

1.  Backbone resonance assignments of human UBC9.

Authors:  Q Liu; B Shen; D J Chen; Y Chen
Journal:  J Biomol NMR       Date:  1999-01       Impact factor: 2.835

Review 2.  Concepts in sumoylation: a decade on.

Authors:  Ruth Geiss-Friedlander; Frauke Melchior
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

3.  The 'rule of three' for fragment-based drug discovery: where are we now?

Authors:  Harren Jhoti; Glyn Williams; David C Rees; Christopher W Murray
Journal:  Nat Rev Drug Discov       Date:  2013-07-12       Impact factor: 84.694

4.  Covalent Inhibition of Ubc13 Affects Ubiquitin Signaling and Reveals Active Site Elements Important for Targeting.

Authors:  Curtis D Hodge; Ross A Edwards; Craig J Markin; Darin McDonald; Mary Pulvino; Michael S Y Huen; Jiyong Zhao; Leo Spyracopoulos; Michael J Hendzel; J N Mark Glover
Journal:  ACS Chem Biol       Date:  2015-05-01       Impact factor: 5.100

5.  Allosteric activation of E2-RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78.

Authors:  Ranabir Das; Jennifer Mariano; Yien Che Tsai; Ravi C Kalathur; Zlatka Kostova; Jess Li; Sergey G Tarasov; Robert L McFeeters; Amanda S Altieri; Xinhua Ji; R Andrew Byrd; Allan M Weissman
Journal:  Mol Cell       Date:  2009-06-26       Impact factor: 17.970

6.  Fragment-based lead discovery grows up.

Authors:  Monya Baker
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

7.  A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.

Authors:  Jessica D Kessler; Kristopher T Kahle; Tingting Sun; Kristen L Meerbrey; Michael R Schlabach; Earlene M Schmitt; Samuel O Skinner; Qikai Xu; Mamie Z Li; Zachary C Hartman; Mitchell Rao; Peng Yu; Rocio Dominguez-Vidana; Anthony C Liang; Nicole L Solimini; Ronald J Bernardi; Bing Yu; Tiffany Hsu; Ido Golding; Ji Luo; C Kent Osborne; Chad J Creighton; Susan G Hilsenbeck; Rachel Schiff; Chad A Shaw; Stephen J Elledge; Thomas F Westbrook
Journal:  Science       Date:  2011-12-08       Impact factor: 47.728

Review 8.  Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design.

Authors:  Xinyuan Duan; John O Trent; Hong Ye
Journal:  Anticancer Agents Med Chem       Date:  2009-01       Impact factor: 2.505

9.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

10.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Authors:  A Lopez-Girona; D Mendy; T Ito; K Miller; A K Gandhi; J Kang; S Karasawa; G Carmel; P Jackson; M Abbasian; A Mahmoudi; B Cathers; E Rychak; S Gaidarova; R Chen; P H Schafer; H Handa; T O Daniel; J F Evans; R Chopra
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

View more
  9 in total

1.  A Small-Molecule Microarray Approach for the Identification of E2 Enzyme Inhibitors in Ubiquitin-Like Conjugation Pathways.

Authors:  Katherine Zlotkowski; William M Hewitt; Ranu S Sinniah; Joseph E Tropea; Danielle Needle; George T Lountos; Joseph J Barchi; David S Waugh; John S Schneekloth
Journal:  SLAS Discov       Date:  2017-01-06       Impact factor: 3.341

2.  An in vitro Förster resonance energy transfer-based high-throughput screening assay identifies inhibitors of SUMOylation E2 Ubc9.

Authors:  Yu-Zhe Wang; Xiao Liu; George Way; Vipul Madarha; Qing-Tong Zhou; De-Hua Yang; Jia-Yu Liao; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2020-04-27       Impact factor: 7.169

3.  A dual protease approach for expression and affinity purification of recombinant proteins.

Authors:  Sreejith Raran-Kurussi; David S Waugh
Journal:  Anal Biochem       Date:  2016-04-19       Impact factor: 3.365

4.  Expression of SUMO associated proteins in the mouse endometrium is regulated by ovarian hormones throughout the estrous cycle.

Authors:  Yi Liu; Xiaofang Ma; Xuhong Chen; Jinsheng Chen; Li Yuan; Lili Li; Yaowu Bai; Xiaozhi Liu
Journal:  Exp Ther Med       Date:  2020-01-03       Impact factor: 2.447

5.  Allosteric mechanism for site-specific ubiquitination of FANCD2.

Authors:  Viduth K Chaugule; Connor Arkinson; Martin L Rennie; Outi Kämäräinen; Rachel Toth; Helen Walden
Journal:  Nat Chem Biol       Date:  2019-12-23       Impact factor: 15.040

Review 6.  The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy.

Authors:  Xiaodi Du; Hongyu Song; Nengxing Shen; Ruiqi Hua; Guangyou Yang
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

Review 7.  Current Status of SUMOylation Inhibitors.

Authors:  Christopher M Brackett; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

Review 8.  Targeting SUMOylation in Plasmodium as a Potential Target for Malaria Therapy.

Authors:  Daffiny Sumam de Oliveira; Thales Kronenberger; Giuseppe Palmisano; Carsten Wrenger; Edmarcia Elisa de Souza
Journal:  Front Cell Infect Microbiol       Date:  2021-06-10       Impact factor: 5.293

9.  Allosteric Targeting of the Fanconi Anemia Ubiquitin-Conjugating Enzyme Ube2T by Fragment Screening.

Authors:  Francesca E Morreale; Alessio Bortoluzzi; Viduth K Chaugule; Connor Arkinson; Helen Walden; Alessio Ciulli
Journal:  J Med Chem       Date:  2017-05-02       Impact factor: 7.446

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.